Skip to main content
User Image

Muath M Alobaida

Assistant Professor

Faculty

Prince Sultan College for emergency medical services
College building No. 2
publication
Journal Article
2025

Evaluating the risk of atrial fibrillation in patients with chronic recurrent pericarditis prescribed colchicine: Observations using TriNetX global federated research network

Background

Chronic pericarditis is associated with significant cardiovascular morbidity, including atrial fibrillation (AF), heart failure (HF), and stroke. Colchicine is widely used in pericarditis management for its anti-inflammatory effects, but its impact on arrhythmias and other cardiovascular outcomes remains uncertain.

Methods

We conducted a retrospective observational cohort study using the TriNetX global federated research network to assess the association between colchicine use and cardiovascular outcomes in in-patients with chronic pericarditis. Patients diagnosed with chronic adhesive and constrictive pericarditis with or without colchicine use between 2010 and 2024 were included. Propensity score matching (PSM) (1:1) was used to balance baseline characteristics. The primary outcome was 1-year incidence of AF. Secondary outcomes included all-cause mortality, ischemic stroke, acute myocardial infarction (AMI), acute HF, cardiac arrest, ventricular arrhythmias, and a composite cardiovascular outcome.

Results

Of 8,120 patients hospitalized with chronic pericarditis, 1,064 received colchicine. 1,061 patients were matched in each group after PSM. The 1-year incidence of AF was similar between colchicine users and non-users (HR: 0.90, 95% CI: 0.76–1.06) after PSM. Colchicine use was associated with significantly lower risk of all-cause mortality (HR: 0.67, 95% CI: 0.54–0.84) and ischemic stroke (HR: 0.45, 95% CI: 0.29–0.67) after PSM. No significant differences were observed for AMI, cardiac arrest, HF, or ventricular arrhythmias.

Conclusion

In this real-world cohort of patients with chronic pericarditis, colchicine did not increase the risk of AF. Colchicine was linked to significantly lower risks of all-cause mortality and ischemic stroke in hospitalized chronic pericarditis patients, suggesting potential systemic cardiovascular benefits.

Publisher Name
European Journal of Clinical Pharmacology
more of publication
publications

ABSTRACT

Background

Data on adverse events in patients developing atrial fibrillation (AF) after cardiac arrest (CA)…

by Muath Alobaida
2026
Published in:
Journal of Cardiovascular Electrophysiology
publications

Abstract

Background

The risk-benefit profile of direct oral anticoagulants (DOACs) in kidney transplant recipients (KTRs) with atrial fibrillation (AF)…

by Muath Alobaida
2026
Published in:
European Journal of Internal Medicine
publications

Background

Chronic pericarditis is associated with significant cardiovascular morbidity, including atrial fibrillation (AF), heart failure (HF), and stroke. Colchicine is widely used in…

by Mert Kaşkal, Tommaso Bucci, Muath Alobaida, Steven Ho Man Lam, Michele Rossi, Enrico Tartaglia, Amir Askarinejad, Andrea Galeazzo Rigutini, Gregory YH Lip, Rebecca AB Burton
2025
Published in:
European Journal of Clinical Pharmacology